Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

818.02 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
MarketBeat Week in Review – 8/5 - 8/9
Stocks were looking for direction to end the week, but next week may bring more volatility with the latest reading on inflation and the start of retail earnings 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Novo Nordisk's Shares Go on a Rollercoaster Ride After Earnings
Novo Nordisk fell over 8% after its earnings release but recovered nearly all of those losses the next day. It needs to increase supplies of semaglutide. 
Via MarketBeat
Topics ETFs
It's Too Soon to Buy the Dip in Weight Loss Drugmakers
Obesity drugs are a hot market and one still accelerating as new treatments are approved and usage widens. The bad news is that much of the growth is priced in. 
Via MarketBeat
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows
Via Investor Brand Network
Amgen's MariTide Weight Loss Potential: Stock Outlook
Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
EQNX::TICKER_START (NYSE:ANVS),(NYSE:PFE),(NYSE:LLY),(NYSE:GSK),(NYSE:NVO) EQNX::TICKER_END 
Via FinancialNewsMedia
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
From FN Media Group LLC
Via GlobeNewswire
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
From FN Media Group LLC
Via GlobeNewswire
Positive News is Driving This Cancer Drug Maker’s Stock Higher
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather 
Via MarketBeat
MarketBeat Week in Review – 7/8 - 7/12
Stocks took investors on quite a ride this week, with the S&P 500 hitting a new record high, then falling back on Thursday before rallying to end the week 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Eli Lilly Finalizes Acquisition Agreement to Acquire Morphic for $3.2 Billion – InsideArbitrage
Via AB Newswire
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been 
Via MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Morphic Holding, Inc. (Nasdaq - MORF), Desktop Metal, Inc. (NYSE - DM), Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR)
From Brodsky & Smith LLC
Via GlobeNewswire
First Choice Neurology Pioneering Neurologists Administer the New FDA-Approved Drug Kisunla
JUPITER, Fla. - July 11, 2024 - PRLog -- First Choice Neurology, the largest neurology group in the United States, is set to make medical history next week as Dr. Jennifer Buczyner and Dr. Jeff Gelblum... 
Via PRLog
Exposures Product Safety
MarketBeat Week in Review – 7/1 - 7/5
The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases 
Via MarketBeat
Exposures Product Safety
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy 
Via MarketBeat
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. 
Via MarketBeat
Exposures Product Safety
The Top 3 Sectors Poised For Growth This Summer
Communications, technology, and healthcare are the three hottest sectors for growth, but not all stocks will rise with the tides. 
Via MarketBeat
Topics ETFs
MarketBeat Week in Review – 6/17 - 6/21
Markets were calmer this week, with the Dow index posting the biggest gains, but it's too early to tell if this is the start of a broader market rally 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Eli Lilly's Stock Surge Driven by GLP-1 Demand
Shares of Eli Lilly stock are about to hit a new all-time high, sponsored by the pending approval of new weight loss drugs 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Alzheimer's Drug Stocks: Investing in Eli Lilly, Biogen, Roche
The race to develop effective Alzheimer's treatments presents significant opportunities and inherent risks for healthcare investors. 
Via MarketBeat
Exposures Product Safety
3 Strong Buy Stocks for a Sizzling Summer Rally
Investors can take a deep breath before the next earnings season, but they should still invest in equities, including these three gems hiding in plain sight 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments 
Via MarketBeat
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
4 Stocks Making New Highs Despite Market Weakness
While the market faced challenges on Friday, Birkenstock, NetApp, Eli Lilly, and Aflac showed notable strength by achieving new 52-week highs. 
Via MarketBeat
LifeMD Can Surge on Its GLP-1 Offerings
LifeMD is a leading telehealth provider that investors should take note of; the company is entering the GLP-1 market, and its stock could soar as a result 
Via MarketBeat
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
From FN Media Group LLC
Via GlobeNewswire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.